29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
22 citations
,
March 2003 in “Steroids” PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.
17 citations
,
April 2016 in “Journal of Investigative Dermatology” KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.
January 2019 in “Springer eBooks” Modified HDL can better deliver drugs and genes, potentially improving treatments and reducing side effects.
66 citations
,
September 1982 in “Biochemical Pharmacology” Liver enzyme helps minoxidil work better for blood vessel relaxation.
February 2026 in “International Journal of Molecular Sciences” 3-Hydroxypropionic acid may help treat hair loss by promoting hair growth in cells.
64 citations
,
March 2008 in “Neuropsychopharmacology”
30 citations
,
July 2019 in “Endocrinology” Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.
September 2022 in “Research Square (Research Square)” 5% topical minoxidil improves hair density and quality in monilethrix patients.
100 citations
,
October 1986 in “Clinical Endocrinology” Alopecia indicates more severe resistance to 1,25-dihydroxyvitamin D.
January 2004 in “Chinese Journal of Blood Purification” Minoxidil effectively manages severe hypertension in hemodialysis patients with minimal side effects.
1′S-1′-Acetoxychavicol acetate may help treat hair loss by reducing oxidative stress.
January 2026 in “Elsevier eBooks”
October 2025 in “International Journal of Cosmetic Science” USPlus® DERM may help hair growth and reduce hair loss.
May 2026 in “Clinical and Experimental Dermatology” Sublingual minoxidil improved hair growth in a 10-year-old boy without side effects.
6 citations
,
November 2010 in “International Journal of Andrology” New oral testosterone formulations show potential for safer, effective hormone replacement in men with low testosterone.
January 2026 in “Journal of Community Medicine and Health Solutions” PP405 shows promise as a new, effective treatment for hair loss with minimal side effects.
January 2011 in “Yearbook of Endocrinology” 11 citations
,
October 1986 in “International Journal of Gynecology & Obstetrics” The contraceptive reduced hair growth and altered hormone levels in hirsute women.
2 citations
,
January 2012 in “Journal of metabolic syndrome” The document concludes that hirsutism can be managed with various treatments tailored to the individual, potentially improving quality of life.
80 citations
,
January 1988 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Spironolactone can cause side effects like irregular bleeding, but lower doses may reduce these effects and still improve hirsutism.
7 citations
,
July 1995 in “PubMed” Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.
March 2020 in “StatPearls” Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.
July 2024 in “Reactions Weekly” January 1997 in “Fundamental & Clinical Pharmacology” 15 citations
,
May 2009 in “Steroids” Certain compounds reduced hamster flank organ size by inhibiting 5α-reductase, like finasteride, without affecting androgen receptors.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
12 citations
,
July 1957 in “Journal of Investigative Dermatology” Giving dihydrotachysterol to mother rats caused skin hardening and bone issues in their babies through milk.
32 citations
,
October 2003 Spironolactone is better than placebo for reducing excessive hair growth in women, but its effectiveness for acne is unclear due to small study sizes.
7 citations
,
January 2015 in “Case reports in endocrinology” The document concludes that HAIR-AN syndrome should be considered when a patient shows severe hyperandrogenism and insulin resistance after excluding tumors.